REG - Immupharma PLC - P140 Program Update

ImmuPharmaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260327:nRSa3539Ya&default-theme=true

RNS Number : 3539Y  Immupharma PLC  27 March 2026

This announcement contains inside information for the purposes of the UK
Market Abuse Regulations ('UK MAR'). Upon publication of this announcement,
this inside information (as defined in UK MAR) is now considered to be in the
public domain. The person responsible for arranging the release of this
announcement on behalf of the Company is tim mccarthy, Chief Executive
Officer.

 

 

27 March 2026

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

P140 Program Update

- patent progress |new supporting data | scientific publication in preparation
-

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development
company, is pleased to provide an update on its auto-immune technology
platform program, P140.

The Company has received a first Combined Search and Examination Report
("CSER") in relation to its United Kingdom patent application for P140, filed
in September 2025. The supportive response is as expected by management at
this stage of the patent examination process and represents an important
positive milestone in the ongoing progress of the application. ImmuPharma
intends, in due course, to build on this filing through a Patent Cooperation
Treaty ("PCT") application, with a view to seeking protection in key
commercial territories. (See notes).

In parallel, ImmuPharma has completed a new study, intended to provide further
supporting data for the patent application. The study was designed to stress
test the associated diagnostic test and strengthen the statistical
significance of the supporting dataset. The Company is pleased to report that
the results were positive and supportive of the patent application.

The scientific team, led by Dr Sébastien Goudreau, CSO, and Dr Laura
Mauran, Head of R&D, is preparing a scientific manuscript describing the
P140 technology platform and its mechanism of action, including recent
supporting data. The Company intends to submit the manuscript to a
peer-reviewed journal in due course. Following publication, the findings will
be shared more broadly with the scientific community.

P140 partnering discussions

As reiterated in recent announcements, P140 remains a core value driver for
ImmuPharma. The Company continues to progress discussions with a number of
potential partners, including under signed confidentiality agreements. The
management team also attended the Bio-Europe Spring healthcare event in Lisbon
this week, where a number of meetings were held in relation to P140.
ImmuPharma remains focused on completing a value‑enhancing licensing deal in
2026.

Dr Sébastien Goudreau, Chief Scientific Officer of ImmuPharma PLC, said:

"The receipt of the first Combined Search and Examination Report for our UK
P140 patent application, together with the new supporting study results,
represents an important step in strengthening the scientific and intellectual
property foundation of the program. In parallel, the scientific manuscript now
in preparation will help the broader scientific community to understand the
unique mechanism of P140 as a precision therapy for patients with Type M
immune disorder. This work reinforces our confidence in P140's potential to
become a first‑in‑class, disease‑modifying approach across multiple
autoimmune diseases."

ImmuPharma will provide further updates on the P140 program as appropriate.

 

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

 
 

Notes to Editors

 

About ImmuPharma PLC

 

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

 

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk) .

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

 

The Patent Cooperation Treaty ("PCT")

 

PCT is an international agreement that allows the applicant to file a single
"international" patent application to keep options open for patent protection
in many countries at once, rather than filing separately in each country on
day one.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSEAEFMEMSEID



            Copyright 2019 Regulatory News Service, all rights reserved